ReviewJHEP reports : innovation in hepatology2019
Anticoagulation in the cirrhotic patient.
Review in JHEP reports : innovation in hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04874428 (Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban and Apixaban in Patients With Compensated Liver Cirrhosis
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Venous thromboembolism in in-hospital cirrhotic patients: A systematic review.Frontiers in medicine · 2022Pooled it
- Machine learning-based risk factors for acute-on-chronic liver failure in alcohol-associated liver disease.Annals of medicine · 2026Observational
- Precision Medicine for Anticoagulation Strategies in the Cath Lab: Part 2.Current cardiology reports · 2026Review
- Bleeding and Thrombotic Risk in Cirrhosis: Hemostatic Profiles from a Single-Center Experience.Life (Basel, Switzerland) · 2026Article
- When Atrial Fibrillation Meets Alcoholic Liver Cirrhosis: Can Direct Oral Anticoagulants Bridge the Therapeutic Gap?Biomedicines · 2026Review
- Safety and efficacy of direct oral anticoagulants in patients with liver cirrhosis: a meta-analysis.Research and practice in thrombosis and haemostasis · 2026Article
- Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide.Journal of clinical medicine · 2025Review
- Outpatient management after hospitalisation for acute decompensation of cirrhosis: A practical guide.World journal of hepatology · 2024Review
- Anticoagulants in cirrhosis: main concerns.Nature reviews. Gastroenterology & hepatology · 2024Article
- Hematological abnormalities in liver cirrhosis.World journal of hepatology · 2024Review
- Review
- Article
- The Challenge of Anticoagulation in Liver Cirrhosis.Visceral medicine · 2024Review
- Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin.Research and practice in thrombosis and haemostasis · 2024Article
- No evidence of association between inherited thrombophilia and increased risk of liver fibrosis.United European gastroenterology journal · 2023Observational
- Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art.World journal of gastroenterology · 2023Review
- Management of splanchnic vein thrombosis.JHEP reports : innovation in hepatology · 2023Review
- Oral Anticoagulation in Patients with Chronic Liver Disease.Medicina (Kaunas, Lithuania) · 2023Review
- Hematohepatology: The potential for direct oral anticoagulant "Inflation" in liver transplant candidates.Research and practice in thrombosis and haemostasis · 2023Article
- Direct Oral Anticoagulants versus Vitamin K Antagonists in Individuals Aged 80 Years and Older: An Overview in 2021.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past, patients with liver cirrhosis were thought to be prone to increased bleeding risk. However, those with compensated liver cirrhosis actually have normal coagulative balance, which can become altered when liver function worsens, or infection, bleeding, or acute kidney insufficiency occur. When this happens, it is now recognized that patients with liver cirrhosis are at higher risk of thrombotic rather than haemorrhagic complications. Anticoagulation plays a favourable role both when used therapeutically or prophylactically. Successful anticoagulation is associated with a lower rate of decompensation and with improved survival. To date, treatment has involved the use of low molecular weight heparins and vitamin K antagonists. Preliminary data suggest that novel non-vitamin K antagonist oral anticoagulants can be used safely in patients with liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.